Phoenix Molecular Designs is a clinical-stage biotechnology company that is developing small molecule kinase inhibitors as a targeted therapy for cancer. We are focused on treating one of the most aggressive types of breast cancer, Triple Negative Breast Cancer (TNBC), which currently has limited durable options. Our patented cancer compounds position us in the lead to fast track our product to market as it fills an unmet medical need. Our cancer therapy has the potential to save lives and improve quality of life.